Wilmington PharmaTech to expand in Delaware; planning new large-scale manufacturing facility

WILMINGTON, Del., Feb. 25, 2019 /PRNewswire/ -- Wilmington PharmaTech, with locations in Newark, Delaware and Suzhou Jiangsu, China, is expanding ? planning to hire up to 139 new employees and invest $18 million in a new state-of-the-science research and manufacturing facility, to be located on 2309 Sunset Lake Road in Newark, Delaware.

Wilmington PharmaTech, in operation since 2003, is a Contract Research/Manufacturing Organization that provides integrated services to pharmaceutical companies and biotech firms to expedite new pharmaceutical product development. One of their main offerings is manufacturing of Active Pharmaceutical Ingredients (API's) and related materials under cGMP, which is an important aspect in the drug development process that is required to ensure product quality and provide consistency during formulation and manufacture.

PharmaTech currently employs 37 full-time staff in the United States in several Newark locations including a 16,000 square foot building at 229A Lake Drive, a 50,000 square foot facility on Sunset Lake Road (previously owned by DuPont) and a 40,000 square foot building at Pencader Drive. 

"Wilmington PharmaTech's expansion shows Delaware's distinctive strength in supporting biotechnology and pharmaceutical start-up companies and builds on a foundation that began more than 200 years ago with the DuPont Company," said Governor John Carney.  "We remain committed to supporting job growth throughout Delaware."  

Dr. Ke Li, PMP®, PharmaTech's Director of Operations, presented the company's growth plans to the Council on Development Finance (CDF) on Monday, February 25, including the plan to build a new, large-scale pharmaceutical production facility. Wilmington PharmaTech requested a $300,400 performance-based grant to support adding new jobs and a grant of $360,000 for assistance with capital costs.

"This marks the next wave of growth, positioning Wilmington PharmaTech as the leader in new drug manufacturing in the US," Said Hui-Yin Harry Li, Ph.D., President and CEO of Wilmington PharmaTech. "This expansion scales up operations and significantly enhances offerings to our clients in API manufacturing and related services. It also expands our portfolio of research, development, and potential commercial API services. PharmaTech's expansion plans fulfill the commitment to growth and its hallmark reputation for excellence for our employees, customers, partners and our community in the state of Delaware."

About Wilmington PharmaTech
Wilmington PharmaTech is a fully integrated Contract Research/Manufacturing Organization (CRO/CMO) specializing in chemical process research and cGMP manufacturing, analytical method development and validation.  The soon-to-be-built Active Pharmaceutical Ingredients (API) manufacturing will serve the growing pharmaceutical, biotech and virtual biotech startups and as a one-stop contract research and manufacturing service provider. To learn more about Wilmington PharmaTech, please visit http://www.wilmingtonpharmatech.com/.

About Delaware Prosperity Partnership
Delaware Prosperity Partnership is a nonprofit that leads the state of Delaware's economic development efforts to attract, grow and retain businesses; to build a stronger entrepreneurial and innovation ecosystem; and to support private employers in identifying, recruiting and developing talent in the state of Delaware.

SOURCE Delaware Prosperity Partnership